During the past decade, Moscow Clinical Scientific Center conducted 32 clinical trials. In the 10-year time frame, 32 clinical trials started and 4 clinical trials were completed, i.e. on average, 12.5% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 4 clinical trials were completed. i.e. 21.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Moscow Clinical Scientific Center" #1 sponsor was "Hoffmann-La Roche" with 11 trials, followed by "Moscow Clinical Scientific Center" with 6 trials sponsored, "Biocad" with 3 trials sponsored, "Shire" with 3 trials sponsored and "Celgene" with 3 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Moscow Clinical Scientific Center" #1 collaborator was "Moscow Clinical Scientific Center" with 2 trials as a collaborator, "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 1 trials as a collaborator, "Acceleron Pharma Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)" with 1 trials as a collaborator, "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator and "Breast International Group" with 1 trials as a collaborator. Other collaborators include 17 different institutions and companies that were collaborators in the rest 27 trials.

According to Clinical.Site data, the most researched conditions in "Moscow Clinical Scientific Center" are "Breast Cancer" (6 trials), "Postoperative Delirium" (3 trials), "Ulcerative Colitis" (3 trials), "Cervical Cancer" (2 trials) and "Melanoma" (2 trials). Many other conditions were trialed in "Moscow Clinical Scientific Center" in a lesser frequency.

Most popular intervention types in "Moscow Clinical Scientific Center" are "Drug" (23 trials), "Other" (5 trials), "Procedure" (5 trials), "Biological" (4 trials) and "Diagnostic Test" (3 trials). Other intervention types were less common.

The name of intervention was led by "Atezolizumab" (9 trials), "Placebo" (9 trials), "Paclitaxel" (6 trials), "BCD-100" (3 trials) and "Bevacizumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Moscow Clinical Scientific Center" are 29 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Moscow Clinical Scientific Center". undefined are not yet recruiting, 11 are recruiting, 10 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Moscow Clinical Scientific Center, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Moscow Clinical Scientific Center, 2 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 14 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 5 trials that are defined as “Not Applicable".